Mer­ck carves out path in first-line ad­vanced cer­vi­cal can­cer with new FDA win for Keytru­da jug­ger­naut

Mer­ck’s PD-(L)1 block­buster Keytru­da has held a steady march in­to ear­li­er lines of ther­a­py, with cer­vi­cal can­cer next up on its check­list. Af­ter flash­ing win­ning …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER